ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00555724
Recruitment Status : Completed
First Posted : November 9, 2007
Last Update Posted : January 9, 2017
Sponsor:
Information provided by (Responsible Party):
Biogen